Cormorant Asset Management, LP Immuneering Corp Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $1.74 Million - $6.65 Million	-909,091 Reduced 21.62%	3,295,273 $9.52 Million
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $11.8 Million - $24.3 Million	1,818,183 Added 76.2%	4,204,364 $42.6 Million
Q1 2023 May 15, 2023	BUY	$3.78 - $10.38 $378,000 - $1.04 Million	100,000 Added 4.37%	2,386,181 $23.2 Million
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $63,971 - $128,435	-16,445 Reduced 0.71%	2,286,181 $12.4 Million
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $806,000 - $1.55 Million	50,000 Added 2.22%	2,302,626 $37.2 Million
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $38.3 Million - $74 Million	2,252,626 New	2,252,626 $58.5 Million

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $55.4M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.